Metallo-drugs in the treatment of malignant pleural mesothelioma

Ilaria Zanellato; Ilaria Bonarrigo; Elisabetta Gabano; Mauro Ravera; Nicola Margiotta; Pier Giacomo Betta; Domenico Osella

doi:10.1016/j.ica.2012.06.005

Metallo-drugs in the treatment of malignant pleural mesothelioma

Ilaria Zanellato
, Ilaria Bonarrigo
, Elisabetta Gabano
, Mauro Ravera
, Nicola Margiotta
, Pier Giacomo Betta
, Domenico Osella

Research output: Contribution to journal › Review article › peer-review

Abstract

Mesothelioma is a rare form of cancer that affects the membranous lining of the chest (pleura) and, less commonly, the lining of the abdomen and heart. The disease carries a poor prognosis and is typically associated with exposure to asbestos, a mineral that has been widely used due to its fire resistance and insulating properties. The standard non-surgical treatment for malignant pleural mesothelioma (MPM) is polychemotherapy combining cisplatin/carboplatin and a second agent with a different mechanism of action. This review outlines the use of clinically approved platinum-drugs and the design of metal-drug candidates for the treatment of MPM.

Original language	English
Pages (from-to)	64-74
Number of pages	11
Journal	Inorganica Chimica Acta
Volume	393
DOIs	https://doi.org/10.1016/j.ica.2012.06.005
Publication status	Published - 1 Dec 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Chemoresistance
Chemotherapy
Malignant mesothelioma
Metal drugs
Platinum drugs

Access to Document

10.1016/j.ica.2012.06.005

Cite this

@article{a924249a99b94c61822f60f95b3b76e4,

title = "Metallo-drugs in the treatment of malignant pleural mesothelioma",

abstract = "Mesothelioma is a rare form of cancer that affects the membranous lining of the chest (pleura) and, less commonly, the lining of the abdomen and heart. The disease carries a poor prognosis and is typically associated with exposure to asbestos, a mineral that has been widely used due to its fire resistance and insulating properties. The standard non-surgical treatment for malignant pleural mesothelioma (MPM) is polychemotherapy combining cisplatin/carboplatin and a second agent with a different mechanism of action. This review outlines the use of clinically approved platinum-drugs and the design of metal-drug candidates for the treatment of MPM.",

keywords = "Chemoresistance, Chemotherapy, Malignant mesothelioma, Metal drugs, Platinum drugs",

author = "Ilaria Zanellato and Ilaria Bonarrigo and Elisabetta Gabano and Mauro Ravera and Nicola Margiotta and Betta, \{Pier Giacomo\} and Domenico Osella",

note = "Funding Information: We thank the Regione Piemonte (Ricerca Sanitaria 2008, Research Project on Rare Diseases), the Provincia di Alessandria (Research Project 2010-0081200) and the CRT Foundation (Research Project “Improvement of Mesothelioma Treatment” 2010) for financial support. The research was carried out within the framework of the European Cooperation COST D39 (Metallo-Drug Design and Action). The Inter-University Consortium for Research on the Chemistry of Metal Ions in Biological Systems (CIRCMSB, Bari, Italy) is gratefully acknowledged for a grant to I.B. ",

year = "2012",

month = dec,

day = "1",

doi = "10.1016/j.ica.2012.06.005",

language = "English",

volume = "393",

pages = "64--74",

journal = "Inorganica Chimica Acta",

issn = "0020-1693",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Metallo-drugs in the treatment of malignant pleural mesothelioma

AU - Zanellato, Ilaria

AU - Bonarrigo, Ilaria

AU - Gabano, Elisabetta

AU - Ravera, Mauro

AU - Margiotta, Nicola

AU - Betta, Pier Giacomo

AU - Osella, Domenico

N1 - Funding Information: We thank the Regione Piemonte (Ricerca Sanitaria 2008, Research Project on Rare Diseases), the Provincia di Alessandria (Research Project 2010-0081200) and the CRT Foundation (Research Project “Improvement of Mesothelioma Treatment” 2010) for financial support. The research was carried out within the framework of the European Cooperation COST D39 (Metallo-Drug Design and Action). The Inter-University Consortium for Research on the Chemistry of Metal Ions in Biological Systems (CIRCMSB, Bari, Italy) is gratefully acknowledged for a grant to I.B.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Mesothelioma is a rare form of cancer that affects the membranous lining of the chest (pleura) and, less commonly, the lining of the abdomen and heart. The disease carries a poor prognosis and is typically associated with exposure to asbestos, a mineral that has been widely used due to its fire resistance and insulating properties. The standard non-surgical treatment for malignant pleural mesothelioma (MPM) is polychemotherapy combining cisplatin/carboplatin and a second agent with a different mechanism of action. This review outlines the use of clinically approved platinum-drugs and the design of metal-drug candidates for the treatment of MPM.

AB - Mesothelioma is a rare form of cancer that affects the membranous lining of the chest (pleura) and, less commonly, the lining of the abdomen and heart. The disease carries a poor prognosis and is typically associated with exposure to asbestos, a mineral that has been widely used due to its fire resistance and insulating properties. The standard non-surgical treatment for malignant pleural mesothelioma (MPM) is polychemotherapy combining cisplatin/carboplatin and a second agent with a different mechanism of action. This review outlines the use of clinically approved platinum-drugs and the design of metal-drug candidates for the treatment of MPM.

KW - Chemoresistance

KW - Chemotherapy

KW - Malignant mesothelioma

KW - Metal drugs

KW - Platinum drugs

U2 - 10.1016/j.ica.2012.06.005

DO - 10.1016/j.ica.2012.06.005

M3 - Review article

SN - 0020-1693

VL - 393

SP - 64

EP - 74

JO - Inorganica Chimica Acta

JF - Inorganica Chimica Acta

ER -

Metallo-drugs in the treatment of malignant pleural mesothelioma

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this